Sugi Predict

Sugi Predict / Compounds / SCHEMBL4456253

SCHEMBL4456253

SCHEMBL4456253

O=C(O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 11/20 0.66
▸ ALOX15 P16050 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ HPGD P15428 2/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ CKS1B P61024 3/20 0.49
▸ SKP1 P63208 3/20 0.49
▸ SKP2 Q13309 3/20 0.49
▸ LMNA P02545 1/20 0.48
▸ NAPRT Q6XQN6 1/20 0.48
▸ P4HTM Q9NXG6 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ ACMSD Q8TDX5 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ NPC1 O15118 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30712642 1.00 CNR1 (0.66) CNR1ALOX15ALDH1A1HPGDHSD17B10
SCHEMBL476267 0.85 CNR1 (0.62) CNR1ALDH1A1CKS1BSKP1SKP2
SCHEMBL2834588 0.85 CNR1 (0.62) CNR1ALDH1A1CKS1BSKP1SKP2
SCHEMBL2704945 0.84 CNR1 (0.67) CNR1LMNAL3MBTL1KDM4EGAA
SCHEMBL4456962 0.84 CNR1 (0.57) CNR1ALOX15ALDH1A1HPGDHSD17B10
SCHEMBL4465958 0.84 CNR1 (0.69) CNR1
SCHEMBL2830367 0.81 CNR1 (0.61) CNR1ALDH1A1SMN1; SMN2
SCHEMBL2837164 0.81 CNR1 (0.57) CNR1CKS1BSKP1SKP2L3MBTL1
SCHEMBL30712635 0.81 CNR1 (0.61) CNR1ALDH1A1SMN1; SMN2
SCHEMBL4451106 0.80 CNR1 (1.00) CNR1ALDH1A1LMNAKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458690-B1 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS ASTRAZENECA AB (SE) 2007-02-21 — — EP claimed
US-20050032808-A1 5 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists ASTRAZENECA AB (SE) 2005-02-10 — — US claimed
EP-1458690-A1 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS Astrazeneca AB (SE) 2004-09-22 — — EP claimed
WO-2003051850-A1 PYRAZINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2003-06-26 — — WO claimed
WO-2003051851-A1 5, 6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS ASTRAZENECA AB (SE) 2003-06-26 — — WO claimed
WO-2024009283-A1 AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-01-11 — — WO disclosed
US-7473693-B2 Stable dispersion of solid particles comprising a water-insoluble pyrazine compound ASTRAZENECA AB (SE) 2009-01-06 — — US disclosed
EP-1638953-B1 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS ASTRAZENECA AB (SE) 2008-08-27 — — EP disclosed
EP-1592451-B1 STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND ASTRAZENECA AB (SE) 2008-07-02 — — EP disclosed
US-7342019-B2 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists ASTRAZENECA AB (SE) 2008-03-11 — — US disclosed
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators ASTRAZENECA AB (SE) 2007-04-26 — — US disclosed
US-20070093505-A1 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators ASTRAZENECA AB (SE) 2007-04-26 — — US disclosed
WO-2004111038-A1 5,6-BIS (4-CHLOROPHENYL)-N-PIPERIDIN1-YL-3-(PIPERIDIN-1-YL-CARBONYL)PYRAZINE-2-CARBOXAMIDE ASTRAZENECA AB (SE) 2004-12-23 — — WO disclosed
WO-2004111039-A1 2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS ASTRAZENECA AB (SE) 2004-12-23 — — WO disclosed
WO-2004111034-A1 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS ASTRAZENECA AB (SE) 2004-12-23 — — WO disclosed
WO-2004111033-A1 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. ASTRAZENECA AB (SE) 2004-12-23 — — WO disclosed
EP-1458690-A1 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS Astrazeneca AB (SE) 2004-09-22 — — EP disclosed
WO-2004069277-A1 STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND ASTRAZENECA AB (SE) 2004-08-19 — — WO disclosed
WO-2003051850-A1 PYRAZINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2003-06-26 — — WO disclosed
WO-2003051851-A1 5, 6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS ASTRAZENECA AB (SE) 2003-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093505-A1 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators CNR2, CNR1, HTR2C CNR1 2/4885ALOX15 1501/4885ALDH1A1 3459/4885
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators CNR2, CNR1, FAAH CNR1 2/4885ALOX15 2228/4885ALDH1A1 3008/4885
US-20050032808-A1 5 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists CNR1, CNR2, GPR18 CNR1 1/4885ALOX15 459/4885ALDH1A1 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.